Anne Marie Droste

Relentlessly optimistic. Excited for biology to fix the world.

[Anne Marie Droste @AmDroste]

@navyadotbio Science is the next research frontier. Can’t compete with those tailwinds. My guess is that the labs will do discovery and own the assets, and partner with pharma for development.

[Anne Marie Droste @AmDroste]

Hot take: most of this value is going to the frontier AI labs

[Adam Draper ⏻ @AdamDraper]

I believe this next wave of Bio is going to be bigger than anyone can imagine.

Multiple $10T companies. Maybe even a 100 Trillion dollar company.

[Anne Marie Droste @AmDroste]

@chorye @rheumrob Out of curiosity - which ones did you try?

[Anne Marie Droste @AmDroste]

Surprisingly fun/helpful offsite activity: work tarot. 🔮

Ask Claude to make you a custom deck based on what it knows about your team & co, write on a set of blank cards, predict the future.

[Teddy Blank @teddypowday]

Your CEO should be strong.

Your CTO should be wise.

Your COO should be wicked, cunning, of mysterious origins, fluent in the dark arts, blurry in pictures,

[Anne Marie Droste @AmDroste]

@ninklefitz I know a sticker that would go well here

[OpenAI @OpenAI]

We’re bringing new capabilities to GPT-Rosalind, a model series purpose-built for life sciences research at enterprise scale.

It brings GPT-5.5’s agentic coding and tool use together with stronger intelligence for drug discovery, analysis, design, and experimental workflows.

https://t.co/SrAJ3Mt7ka

[Anne Marie Droste @AmDroste]

@SGRodriques Congrats team!

[OpenAI @OpenAI]

Introducing GPT-Rosalind, our frontier reasoning model built to support research across biology, drug discovery, and translational medicine.

[Sid Sijbrandij @sytses]

Looking forward to speaking at OpenAI Forum in a week on how I leveraged ChatGPT to find cancer treatment options after doctors said there was nothing left for me to do.

https://t.co/iO26Nizrym

[Anne Marie Droste @AmDroste]

The Rosie story is AI doing the *information* work. Humans still ran the lab.

Now imagine when agents close that loop.

(Also the biotech pile-on is very predictable and quite boring. Good for Rosie, and the optimists are on the right side of history.)

[vittorio @IterIntellectus]

this is actually insane

> be tech guy in australia
> adopt cancer riddled rescue dog, months to live
> not_going_to_give_you_up.mp4
> pay $3,000 to sequence her tumor DNA
> feed it to ChatGPT and AlphaFold
> zero background in biology
> identify mutated proteins, match them to drug targets
> design a custom mRNA cancer vaccine from scratch
> genomics professor is “gobsmacked” that some puppy lover did this on his own
> need ethics approval to administer it
> red tape takes longer than designing the vaccine
> 3 months, finally approved
> drive 10 hours to get rosie her first injection
> tumor halves
> coat gets glossy again
> dog is alive and happy
> professor: “if we can do this for a dog, why aren’t we rolling this out to humans?”

one man with a chatbot, and $3,000 just outperformed the entire pharmaceutical discovery pipeline.

we are going to cure so many diseases.
I dont think people realize how good things are going to get

[Anne Marie Droste @AmDroste]

@elspeth_lawson @Alicebentinck @matthewclifford Jealous that you all get to work together <3

[Anne Marie Droste @AmDroste]

Learned from the very very best.

Huge congrats to @Alicebentinck and @matthewclifford + the excellent EF team.

Only the beginning!

[Alice Bentinck @Alicebentinck]

Today, we're announcing @join_EF's Series D: $200M of fresh capital, at a unicorn+ valuation.

We're in a golden age of entrepreneurship. More individuals than ever before are taking the leap, with the world's most transformative technology at their fingertips.

For over a decade, we've backed extraordinary people without asking what idea they're working on. We call this Talent Investing; believing in someone from Day 1 and giving them the peer group, environment, and capital to find their life's work.

And it works! Companies built through EF are now worth $16bn, up from $3bn at our last raise in 2021.

Thank you to our investors for their continued belief, the EF team for bringing this vision to life, and the founders who rejected the status quo to build globally important companies with us.

And, of course, a huge thank you to @matthewclifford, my exceptional cofounder.

[Anne Marie Droste @AmDroste]

@ali_susskind You did that!

[Sam Rodriques @SGRodriques]

Robust benchmarks are the foundation on which progress in AI is built. Benchmarks for science, in particular, are extremely hard to build, but good ones are important to move the field forward.

This is a great piece from Science today, which charts progress in building new benchmarks for science: https://t.co/9A8JDQocGe

[Kevin Weil 🇺🇸 @kevinweil]

💥 Today we’re introducing Prism—a free, AI-native workspace for scientists to write and collaborate on research, powered by GPT-5.2.

Accelerating science requires progress on two fronts:
1. Frontier AI models that use scientific tools and can tackle the hardest problems
2. Integrating that AI into the products scientists use every day

Prism is free to anyone with a ChatGPT account, with unlimited projects and collaborators.

Try it today at https://t.co/cmEsJYRtW9—would love to hear your feedback.

[Anne Marie Droste @AmDroste]

At #NeurIPS2025 - anyone want to go for a surf?

[Anne Marie Droste @AmDroste]

@abhinadduri @arcinstitute Hi! Would love to meet!

[Anne Marie Droste @AmDroste]

@harshit_sikchi @OpenAI Hi!

[Anne Marie Droste @AmDroste]

@anthonycosta Yes please!